Keros Therapeutics CFO Keith Regnante Resigns, Effective Aug. 3; VP Finance Annita Tanini Named Interim Principal Financial Officer

Keros Therapeutics

Keros Therapeutics

KROS

0.00

https://www.sec.gov/ix?doc=/Archives/edgar/data/1664710/000166471026000038/kros-20260717.htm